Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Full Prescribing Information, Copaxone (glatiramer acetate)
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
AB Science announces recruitment of first patient in phase 3 study of masitinib in progressive multiple sclerosis
Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD.
Risk factors for convertion to clinically defined multiple sclerosis after clinically isolated syndrome in a racially mixed Brazilian cohort.
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union
[Prevalence of multiple sclerosis in the Region of Murcia].
The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities.
Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment.
Myelinating satellite oligodendrocytes are integrated in a glial syncytium constraining neuronal high-frequency activity.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Teriflunomide
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
Personality in multiple sclerosis (MS): impact on health, psychological well-being, coping, and overall quality of life.
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview.
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients
A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.
Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Improvements in cognition, quality of life, and physical performance with clinical Pilates in multiple sclerosis: a randomized controlled trial.
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.
Potassium channel KIR4.1 as an immune target in multiple sclerosis.
Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.
[Information processing speed and influential factors in multiple sclerosis].
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Pages
« first
‹ previous
…
38
39
40
41
42
43
44
45
46
…
next ›
last »